This is the first study to prospectively evaluate the clinical value of novel biomarkers (IL-6, MPO, TNF-alpha) in cancer patients as potential biomarkers of cancer therapy-related cardiac dysfunction, defined according to current ESC cardio-oncology guidelines. This evidence concerns the gene MPO and cancer.